...
首页> 外文期刊>AMB Express >Inhibiting avian influenza virus shedding using a novel RNAi antiviral vector technology: proof of concept in an avian cell model
【24h】

Inhibiting avian influenza virus shedding using a novel RNAi antiviral vector technology: proof of concept in an avian cell model

机译:使用新型RNAi抗病毒载体技术抑制禽流感病毒脱落:禽细胞模型中概念的证明

获取原文

摘要

Influenza A viruses pose significant health and economic threats to humans and animals. Outbreaks of avian influenza virus (AIV) are a liability to the poultry industry and increase the risk for transmission to humans. There are limitations to using the AIV vaccine in poultry, creating barriers to controlling outbreaks and a need for alternative effective control measures. Application of RNA interference (RNAi) techniques hold potential; however, the delivery of RNAi-mediating agents is a well-known obstacle to harnessing its clinical application. We introduce a novel antiviral approach using bacterial vectors that target avian mucosal epithelial cells and deliver (small interfering RNA) siRNAs against two AIV genes, nucleoprotein (NP) and polymerase acidic protein (PA). Using a red fluorescent reporter, we first demonstrated vector delivery and intracellular expression in avian epithelial cells. Subsequently, we demonstrated significant reductions in AIV shedding when applying these anti-AIV vectors prophylactically. These antiviral vectors provided up to a 10,000-fold reduction in viral titers shed, demonstrating in vitro proof-of-concept for using these novel anti-AIV vectors to inhibit AIV shedding. Our results indicate this siRNA vector technology could represent a scalable and clinically applicable antiviral technology for avian and human influenza and a prototype for RNAi-based vectors against other viruses.
机译:甲型流感病毒对人类和动物构成重大的健康和经济威胁。禽流感病毒(AIV)的爆发是家禽业的责任,并增加了传播给人类的风险。在禽类中使用AIV疫苗存在局限性,为控制疫情爆发设置了障碍,并且需要其他有效的控制措施。 RNA干扰(RNAi)技术的应用具有潜力。然而,RNAi介导剂的递送是利用其临床应用的众所周知的障碍。我们介绍了一种新型的抗病毒方法,该方法使用靶向禽类粘膜上皮细胞的细菌载体,并针对两种AIV基因(核蛋白(NP)和聚合酶酸性蛋白(PA))递送(小干扰RNA)siRNA。使用红色荧光报告基因,我们首先证明了禽类上皮细胞中的载体递送和细胞内表达。随后,当预防性应用这些抗AIV载体时,我们证明了AIV脱落的显着减少。这些抗病毒载体可使病毒滴度降低高达10,000倍,证明了使用这些新型抗AIV载体抑制AIV脱落的体外概念验证。我们的结果表明,这种siRNA载体技术可以代表针对禽和人流感的可扩展且可临床应用的抗病毒技术,以及针对其他病毒的基于RNAi的载体的原型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号